Survival in pulmonary arterial hypertension, associated with connective tissue diseases, treated by sildenafil: results of the prospective study


Cite item

Full Text

Abstract

Aim. To investigate the effect of sildenafil on the survival of patients with pulmonary arterial hypertension (PAH) associated with connective tissue diseases (CTD), who have been followed up at the Rheumatology Expert Center. Subjects and methods. A total of 16 patients (all women) with PAH associated with CTD, who had been admitted to the V.A.Nasonova Research Institute of Rheumatology in 2013—2015, were examined. PAH corresponded to Functional Class II in the majority of the patients. After the diagnosis was verified by catheterization of the right heart and pulmonary artery, all the patients reсeived original sildenafil (a phosphodiesterase type 5 inhibitor, a potent vasodilator, the efficiency of which was proven in patients with PAH) at a dose of 20 mg thrice daily. Survival rates and time to clinical deterioration were estimated during a prospective follow-up). Results. Three-year survival rates were 94% in the study group and 25% in the group of historical control (p<0.05). The time to clinical deterioration was associated with the duration of the follow-up and hemodynamic parameters (right atrial pressure and changes in vascular resistance within 4 months after therapy initiation). Conclusion. The administration of sildenafil substantially improves survival in patients with PAH associated with CTD as compared with the historical control. The identification of poor prognostic factors in this cohort of patients and early diagnosis will favor the personification of therapy for the fatal manifestation of CTD.

References

  1. Легочная гипертензия. Под ред. И.Е. Чазовой и Т.В. Мартынюк. М.: Практика; 2015.
  2. Волков А.В. Легочная артериальная гипертензия при системных заболеваниях соединительной ткани. Научно-практическая ревматология. 2015;1(53):69-77.
  3. Волков А.В., Мартынюк Т.В., Юдкина Н.Н., Данилов Н.М., Глухова С.И., Гусева Н.Г., Чазова И.Е., Насонова В.А. Выживаемость пациентов с легочной артериальной гипертензией, ассоциированной с системной склеродермией. Терапевтический архив. 2012;5:24-28.
  4. Koh ET, Lee P, Gladman DD, Abu-Shakra M. Pulmonary hypertension in systemic sclerosis: an analysis of 17 patients. Br J Rheumatol. 1996;35:989-993.
  5. Fagan KA, Badesch DB. Pulmonary hypertension associated with connective tissue disease. Prog Cardiovasc Dis. 2002;45:225-224.
  6. Humbert M, Morrell NW, Archer SL, et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol. 2004;43:13S-24S.
  7. Волков А.В., Мач Э.С., Гусева Н.Г. Дисфункция эндотелия при системной склеродермии — клинико-патогенетические корреляции. Терапевтический архив. 2008;80(10):68-71.
  8. Rubin LJ, Badesch DB, Barst RJ et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002;346:896-903.
  9. Gruenig E, Michelakis E, Vachiéry JL et al. Acute hemodynamic effects of single-dose sildenafil when added to established bosentan therapy in patients with pulmonary arterial hypertension: results of the COMPASS-1 study. J Clin Pharmacol. 2009;49(11): 1343-1352.
  10. Badesch DB, Tapson VF, McGoon MD et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med. 2000;132:425-434.
  11. Ghofrani HA, Rose F, Schermuly RT et al. Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. J Am Coll Cardiol. 2003;42(1):158-164.
  12. D’Alto M. An update on the use of ambrisentan in pulmonary arterial hypertension. Ther Adv Respir Dis. 2012;6(6):331-343.
  13. Волков А.В., Юдкина Н.Н., Николаева Е.В., Курмуков И.А., Насонов Е.Л. Бозентан: существенное увеличение продолжительности жизни пациентов с легочной артериальной гипертонией, ассоциированной с системными ревматическими заболеваниями. Терапевтический архив. 2014;86(5):32-39.
  14. Мартынюк Т.В., Зыков К.А., Антонова О.Ю., Рвачева А.В., Архипова О.А., Кобаль Е.А., Масенко В.П., Чазова И.Е. Влияние бозентана на клинический статус и клеточное звено иммунитета у больных идиопатической легочной гипертензией. Терапевтический архив. 2013;85(1):25-31.
  15. Авдеев С.Н., Царева Н.А., Неклюдова Г.В., Чучалин А.Г. Первый клинический опыт применения антагониста рецепторов эндотелина бозентана у пациентов с легочной артериальной гипертензией: результаты годичного исследования. Терапевтический архив. 2013;85(3):38-43.
  16. Волков А.В., Юдкина Н.Н., Курмуков И.А., Николаева Е.А., Насонов Е.Л. Влияние силденафила на клинические проявления и гемодинамические показатели у больных легочной артериальной гипертензией, ассоциированной с системными ревматическими заболеваниями. Системные гипертензии. 2014;11(3):61-66.
  17. Corbin JD, Francis SH. Cyclic GMP phosphodiesterase-5: Target of sildenafil. J Biol Chem. 1999;274:13729-13732.
  18. Ghofrani HA, Voswinckel R, Reichenberger F et al. Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: A randomized prospective study. J Am Coll Cardiol. 2004;44:1488-1496.
  19. Tantini B, Manes A, Fiumana E et al. Antiproliferative effect of sildenafil on human pulmonary artery smooth muscle cells. Basic Res Cardiol. 2005;100:131-138.
  20. Sastry BK, Narasimhan C, Reddy NK, Raju BS. Clinical efficacy of sildenafil in primary pulmonary hypertension: A randomized, placebo-controlled, double-blind, crossover study. J Am Coll Cardiol. 2004;43:1149-1153.
  21. Watanabe H, Ohashi K, Takeuchi K et al. Sildenafil for primary and secondary pulmonary hypertension. Clin Pharmacol Ther. 2002;71(5):398-402.
  22. Galie N, Ghofrani HA, Torbicki A et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005;353: 2148-2157.
  23. Badesch DB, Hill NS, Burgess et al. Sildenafil for Pulmonary Arterial Hypertension Associated with Connective Tissue Disease. J Rheumatol. 2007;34:2417-2422.
  24. Чазова И.Е., Авдеев С.Н., Царева Н.А., Волков А.В., Мартынюк Т.В., Наконечников С.Н. Клинические рекомендации по диагностике и лечению легочной гипертонии. Терапевтический архив. 2014;86(9):4-23.
  25. Launay D, Remy-Jardin M, Michon-Pasturel U et al. High resolution computed tomography in fibrosing alveolitis associated with systemic sclerosis. J Rheumatol. 2006;33:1789-1801.
  26. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002;166:111-117.
  27. Chemla D, Castelain V, Hervé P, Lecarpentier Y, Brimioulle S. Haemodynamic evaluation of pulmonary hypertension. Eur RespirJ. 2002;20:1314-1331.
  28. Benza RL, Gomberg-Maitland M, Miller DP et al. The REVEAL Registry Risk Score Calculator in Patients Newly Diagnosed With Pulmonary Arterial Hypertension. Chest. 2012;141(2):354-362.
  29. Launay D, Sitbon O, Le Pavec J, Savale L, Tchérakian C, Yaïci A, Achouh L, Parent F, Jais X, Simonneau G, Humbert M. Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil. Rheumatology (Oxford). 2010;49(3):490-500.
  30. Rubin LJ, Badesch DB, Fleming TR, Galiè N, Simonneau G, Ghofrani HA, Oakes M, Layton G, Serdarevic-Pehar M, McLaughlin VV, Barst RJ; SUPER-2 Study Group. Long-term treatment with sildenafil citrate in pulmonary arterial hypertension: the SUPER-2 study. Chest. 2011;140(5):1274-1283.
  31. Galiè N, Rubin Lj, Hoeper M, Jansa P, Al-Hiti H, Meyer G, Chiossi E, Kusic-Pajic A, Simonneau G. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet. 2008;371(9630):2093-2100.
  32. Simonneau G, Galiè N, Jansa P, Meyer GM, Al-Hiti H, Kusic-Pajic A, Lemarié JC, Hoeper MM, Rubin LJ. Long-term results from the EARLY study of bosentan in WHO functional class II pulmonary arterial hypertension patients. Int J Cardiol. 2014;172(2):332-339.
  33. Campo A, Mathai SC, Le Pavec J, Zaiman AL, Hummers LK, Boyce D, Housten T, Champion HC, Lechtzin N, Wigley FM, Girgis RE, Hassoun PM. Hemodynamic predictors of survival in scleroderma-related pulmonary arterial hypertension. Am J Respir Crit Care Med. 2010;182(2):252-260.
  34. Chung L, Farber HW, Benza R, Miller DP, Parsons L, Hassoun PM, McGoon M, Nicolls MR, Zamanian RT. Unique predictors of mortality in patients with pulmonary arterial hypertension associated with systemic sclerosis in the REVEAL registry. Chest. 2014;146(6):1494-1504.

Copyright (c) 2015 Volkov A.V., Nikolaeva E.V., Yudkina N.N., Kurmukov I.A., Nasonov E.L.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

© 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies